The long-term efficacy and safety of new biological therapies for psoriasis

por Papp, Kim A.
Publicado 2006

The safety of etanercept for the treatment of plaque psoriasis

por Papp, Kim A
Publicado 2007

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast

por Gooderham, Melinda, Papp, Kim
Publicado 2015

Evaluation of efalizumab using safe psoriasis control

por Papp, Kim A, Henninger, Eric
Publicado 2006

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

por Papp, Kim A, Toth, Darryl, Rosoph, Les
Publicado 2006

A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris

por Taraska, Victoria, Tuppal, Raj, Olesen, Martin, Bang Pedersen, Claus, Papp, Kim
Publicado 2016

Immunosuppressive therapy in dermatology and PML

por Sterry, Wolfram, Bagot, Martine, Ferrandiz, Carlos, Kragballe, Knud, Papp, Kim, Stingl, Georg
Publicado 2009

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Con...

por Papp, Kim A., Armstrong, April W., Reich, Kristian, Karunaratne, Mahinda, Valdecantos, Wendell
Publicado 2015

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis

por Gooderham, Melinda J., Lynde, Charles, Turchin, Irina, Avadisian, Miriam, Labelle, Melanie, Papp, Kim A.
Publicado 2021

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis

por Anil Kumar, Mysore S., Papp, Kim, Tainaka, Ryo, Valluri, Udaya, Wang, Xuegong, Zhu, Tong, Schwabe, Christian
Publicado 2018

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

por Papp, Kim A., de Vente, Saskia, Zeng, Jiewei, Flack, Mary, Padilla, Byron, Tyring, Stephen K.
Publicado 2021

Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model

por Papp, Kim A., Soliman, Ahmed M., Done, Nicolae, Carley, Christopher, Lemus Wirtz, Esteban, Puig, Luis
Publicado 2021

Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review

por Papp, Kim A., Dhadwal, Gurbir, Gooderham, Melinda, Guenther, Lyn, Turchin, Irina, Wiseman, Marni, Yeung, Jensen
Publicado 2021

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomi...

por Strand, Vibeke, Fiorentino, David, Hu, ChiaChi, Day, Robert M, Stevens, Randall M, Papp, Kim A
Publicado 2013

Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Charac...

por Lebwohl, Mark G., Papp, Kim A., Mørch, Marie Holst, Bernasconi, Marie Y. Jablonski, Warren, Richard B.
Publicado 2021

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series

por Lowes, Michelle A, Chamian, Francesca, Abello, Maria V, Leonardi, Craig, Dummer, Wolfgang, Papp, Kim, Krueger, James G
Publicado 2007

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials

por Silverberg, Jonathan I., Boguniewicz, Mark, Hanifin, Jon, Papp, Kim A., Zhang, Haixin, Rossi, Ana B., Levit, Noah A.
Publicado 2022

Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1

por Kristensen, Lars Erik, Soliman, Ahmed M, Papp, Kim, White, Douglas, Barcomb, Lisa, Lu, Wenjing, Eldred, Ann, Behrens, Frank
Publicado 2022

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results...

por Armstrong, April W., Reich, Kristian, Foley, Peter, Han, Chenglong, Song, Michael, Shen, Yaung-Kaung, You, Yin, Papp, Kim A.
Publicado 2018

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

por Lebwohl, Mark G., Blauvelt, Andrew, Menter, Alan, Papp, Kim A., Guenthner, Scott, Pillai, Radhakrishnan, Israel, Robert J., Jacobson, Abby
Publicado 2019